Results 91 to 100 of about 21,074 (263)
PharmacoepidemiologyBackground: Incretin mimetics, including glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonist) and dipeptidyl peptidase-4 (DPP-4) inhibitors, have been increasingly utilized for glycemic control in patients with type 2 diabetes (T2D ...
Michael W. Strand +3 more
doaj +1 more source
Evaluating EndoC βH5 pseudoislets as a model for human islet transplantation
Diabetic Medicine, EarlyView.Abstract Aims The EndoC βH5 cell line represents a promising human β‐cell model for preclinical diabetes research. Indeed, EndoC βH5 cells aggregate into islet‐like organoids, secrete insulin in a glucose‐dependent manner, and express a variety of β‐cell functional markers.
Lydia F. Daniels Gatward +11 more
wiley +1 more source
Metabolic and Digestive Functions of Glucagon-Like Peptide-1 in Pigs
Folia VeterinariaGlucagon-like peptide-1 (GLP-1) is a hormone with multiple biological effects that plays a key role in glucose metabolism, digestion, and energy homeostasis.
Čulka Ľubomír +3 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris +5 more
wiley +1 more source
Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity
Periodontology 2000, EarlyView., 2023 Abstract Noncommunicable diseases (NCDs) are multifactorial, long‐term, chronic conditions that represent a burden to health‐care systems worldwide as they can only be controlled rather than cured; hence, they require long‐term care. With the exponential increase in NCDs, the occurrence of individuals presenting with more than one chronic disease is ...
Crystal Marruganti +2 more
wiley +1 more source
Luseogliflozin restores GIP responsiveness in diabetic male mice with preserved β‐cell function
Physiological ReportsImpaired glucose‐dependent insulinotropic polypeptide (GIP)‐induced insulin secretion is a characteristic feature of type 2 diabetes, whereas glucagon‐like peptide‐1 (GLP‐1) responsiveness is relatively preserved. Our previous study proposed that chronic
Quan Yingyue +4 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble +7 more
wiley +1 more source
Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background Tirzepatide has demonstrated substantial weight‐loss efficacy in clinical trials, but real‐world evidence from routine digital prescribing remains limited. Methods We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 and July 2025. Linked order‐
Onayomi Rosenior‐Patten +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Abdulhameed Alhazmi, Carel W. le Roux
wiley +1 more source